All In Biotech

Drug Trial Radar · NCT06606483

A Study to Evaluate the Efficacy and Safety of MDR-001 in Subjects Who Are Obesity or Overweight

A 24 Weeks, Multicenter, Randomized, Double-blind, Placebo, Parallel-controlled Phase IIb Trail Comparing the Efficacy and Safety of MDR-001 Tablet Versus Placebo in Subjects With Overweight or Obesity

Last checked: Nov 19, 2026Latest source record: Sep 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

300

Planned (sponsor's estimate)

Start

Sep 23, 2024

Primary completion

Jul 30, 2025

Study completion Sep 30, 2025

Sponsor

Lead sponsor
MindRank AI LtdIndustry
Sponsor type
Industry
First posted
Sep 23, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 24 weeks, multicenter, randomized, double-blind, placebo, parallel-controlled Phase IIb trail comparing the efficacy and safety of MDR-001 tablet versus placebo as an adjunct to a reduced calorie diet and increased physical activity in subjects with overweight or obesity, and to explore the optimal dose selection to support the subsequent Pivotal trial.

Conditions

  • Obesity
  • Overweight and Obesity

Interventions

  • MDR-001Drug

    Oral administration of small molecule MDR-001 tablets

  • PlaceboDrug

    Administered orally placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change in Body Weight From Baseline at Week 24Time frame: Baseline, Week 24

Locations

19 sites in 1 country. Site status is shown where the registry gives one.

  • The Second Hospital Of Anhui Medical University

    Hefei, Anhui, China

  • The People's Hospital of Suancheng City

    Xuancheng, Anhui, China

  • Zibo Central Hospital

    Zibo, Anhui, China

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China

  • The Third People's Hospital of Hainan

    Haikou, Hainan, China

  • The Second Hospital Of Hebe Medical University

    Shijiazhuang, Hebei, China

  • The Fourth Affiliated Hospital of Harbin Medical University

    Harbin, Heilongjiang, China

  • The first Affiliated Hospital of Henan University of Science and Technology

    Luoyang, Henan, China

  • The First Affiliated Hospital of Nanyang Medical College

    Nanyang, Henan, China

  • The First People's Hospital of Chenzhou City

    Chenzhou, Hunan, China

  • Zhuzhou Central Hospital

    Zhuzhou, Hunan, China

  • Second Hospital of Jilin University

    Changchun, Jilin, China

  • Daqing People's Hospital

    Daqing, Jilin, China

  • Panjin Liaoyou Gem Flower Hospital

    Panjin, Liaoning, China

  • The Fifth People's Hospital of Shenyang

    Shenyang, Liaoning, China

  • Central hospital of Jinan

    Jinan, Shandong, China

  • Shanxi Bethune Hospital

    Taiyuan, Shanxi, China

  • Xianyan Hospital of Yanan Univisity

    Xianyang, Shanxi, China

  • Yichang Central People's Hospital

    Yichang, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.